Hedge Funds Adjust Stakes in Regeneron and Repligen

Carmignac Gestion increased its holding in Regeneron Pharmaceuticals by 133.3% in the first quarter, bringing its position to 116,571 shares worth about $90 million, or roughly 0.11% of the company. The fund now lists Regeneron as its 20th largest holding, representing about 1.4% of its portfolio.

Perceptive Advisors LLC reduced its stake in Repligen Corporation by 11.1% during the same period, selling 35,000 shares and ending the quarter with 280,541 shares valued at roughly $33 million, or about 0.5% of Repligen. The move reflects a modest pull‑back by the hedge fund in the biotechnology firm.